Statistics

Total Visits

Views
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer13

Select a period of time:

Number of views in the range

Views
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer7

Views

Views
May 20244
June 20242
July 20240
August 20241
September 20240
October 20240
November 20240
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States7
 

Top cities views

Views
Prineville1